SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Masks cut transmission rates - conference hears
Mon September 28th - Consistent wearing of masks together with social distancing and regular handwashing are effective means of preventing the spread of COVID-19, a European conference of infectious disease experts has heard. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Indigestion drug may ease mild-moderate Covid-19 symptoms

Friday June 5th 2020

A widely available drug used to ease indigestion could help to treat people with mild to moderate cases of Covid-19, it was claimed today.

A small case study of 10 people in the USA found that taking famotidine helped to ease their Covid-19 symptoms ease within 24 to 48 hours of taking the drug, which has led to calls for a clinical trial.

Writing in Gut, the researchers say improvement was evident across all symptom categories assessed, but respiratory symptoms, such as cough and shortness of breath, improved more rapidly than systemic symptoms, such as fatigue.

The severity of five main symptoms: cough; shortness of breath; fatigue; headache and loss of taste/smell as well as general unwellness, was measured using a version of a four-point scale normally applied to assess the severity of cancer symptoms (ECOG PS).

Seven of the patients tested positive for Covid-19, using a swab test, while two had antibodies to the infection. One patient was not tested but was diagnosed with the infection by a doctor.

The patients, six men and four women, aged between 23 and 71, were from a diverse range of ethnic backgrounds and known risk factors for Covid-19 severity, including high blood pressure and obesity. None needed hospital treatment for the virus.

All of them started taking famotidine when they were feeling very poorly with the virus, having suffered symptoms from two to 26 days at that point.

Most took 80mg of famotidine, three times a day, with the average treatment period lasting 11 days, but ranging from five to 21 days.

All 10 patients said that symptoms quickly improved within 24-48 hours of starting famotidine and had mostly cleared up after 14 days.

The researchers say that while their initial findings are promising, they might have been affected by ‘the placebo effect,’ and/or hazy recall.

“Our case series suggests, but does not establish, a benefit from famotidine treatment in outpatients with Covid-19,” they write. “And it’s not clear how famotidine might work: if it might incapacitate the virus in some way or alter a person’s immune response to it.

“Clinically, we unreservedly share the opinion that well-designed and informative studies of efficacy are required to evaluate candidate medications for Covid-19 as for other diseases.”

A clinical trial, testing the combination of famotidine with hydroxychloroquine in patients admitted to hospital with Covid-19, is already under way.

Janowitz T, Gablenz E, Pattinson D et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut 5 June 2020; doi 10.1136/gutjnl-2020-321852

https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-321852

Tags: Flu & Viruses | Gastroenterology | North America | Pharmaceuticals

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES